Supriya Lifescience, a global leader in Active Pharmaceutical Ingredients (APIs) with a cGMP-certification has been awarded the Maharashtra State Export Award by the Government of Maharashtra for excellence in export for the FY 2022–23 and 2023–24...
The Food and Drug Administration (FDA) in Haryana has intensified its efforts to counter the issue of adulteration of pharmaceutical ingredients, and recently issued a "Most Urgent" alert to increase scrutiny of propylene glycol (PG), which is...
AstraZeneca Pharma India Limited will be introducing Lokelma (Sodium Zirconium Cyclosilicate powder) for oral suspension in November 2025.
Marksans Pharma Limited, a major global pharmaceutical company based in Mumbai, has revealed a significant regulatory achievement for its UK operations.
Syngene International, a worldwide contract research, development, and manufacturing organization (CRDMO), has announced enhancements to its facilities aimed at expediting drug discovery and development processes, thereby assisting clients
Healthium Medtech, a global medical technology company with an expanding portfolio spanning surgical, post-surgical, advanced wound care, arthroscopy, and infection prevention, has entered into an exclusive partnership with Tisgenx, Inc.—a U.S.-based
.jpeg "Reliance Life Gets CDSCO Nod for Nivolumab Trial")
CDSCO has given approval to Reliance Life Sciences Pvt. Ltd. for conducting a Phase I/III clinical trial of its biosimilar Nivolumab (R-TPR-067, RLS-Nivolumab). The approval is subsequent to the Subject Expert Committee (Oncology).
Cloudnine Hospitals, one of the largest chains in India focusing on maternity and paediatric care, is in advanced talks to acquire Apollo Cradle and Children’s Hospital (ACCHL) in a deal of approximately Rs 1,500 crore, according to sources...
Maverick Simulation Solutions, a frontrunner in the field of advanced medical simulation technology, has achieved a significant milestone by installing India’s first Anatomage Table at Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital
Boehringer Ingelheim got the green light from the U.S. Food and Drug Administration (FDA) for JASCAYD (nerandomilast) tablets, allowing the addition of a new oral drug to the treatment modalities of adult patients
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")